RADIOPHARMACEUTICAL THERAPY OF LYMPHOMA

Course overview

UAN: 0018-0000-18-204-H01-P UAN: 0018-0000-18-204-H01-T RELEASE: 10/22/2018 EXPIRE: 10/22/2021 CREDITS: 1.0 LEARNING OBJECTIVES: 1. Understand the incidence, prevalence, staging and various treatments for Non-Hodgkin¿s Lymphoma (NHL). 2. Describe radioimmunotherapy and its role in treating NHL. 3. Describe the use of radiolabeled antibodies for treating NHL including patient selection, dosing, side effects and patient response. 4. Describe the development, mechanism of action, treatment regimen for Zevalin¿. 5. List the steps involved in the treatment of a NHL patient with Zevalin¿. 6. Describe the inclusion parameters and patient dosage preparation of Zevalin¿. 7. List the common side effects and serious side effects of Zevalin¿. NOTE: An annual subscription for Purdue¿s nuclear pharmacy recertification program provides access to both the continuing education component of the program and the ¿Radiopharmacy Portal,¿ a reference resource for practitioners. Subscriptions to the continuing educational offerings, which have been accredited through ACPE and BPS, can be purchased for an annual fee of $195 for nuclear pharmacists and $95 for nuclear pharmacy technicians.